Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Lowered by Wall Street Zen

Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by stock analysts at Wall Street Zen to a “strong sell” rating in a research note issued to investors on Saturday.

Other research analysts have also recently issued reports about the company. Barclays reissued an “equal weight” rating and set a $1.00 price objective (down from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.33.

Sangamo Therapeutics Trading Up 4.4%

SGMO stock opened at $0.54 on Friday. Sangamo Therapeutics has a 1-year low of $0.36 and a 1-year high of $1.40. The firm has a market cap of $180.19 million, a P/E ratio of -1.22 and a beta of 1.28. The business’s 50 day moving average is $0.44 and its 200-day moving average is $0.52.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.08). Sangamo Therapeutics had a negative return on equity of 813.95% and a negative net margin of 331.28%.The company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $34.40 million. Sell-side analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SGMO. R Squared Ltd lifted its position in Sangamo Therapeutics by 22.2% during the 4th quarter. R Squared Ltd now owns 147,191 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 26,732 shares in the last quarter. Meritage Portfolio Management lifted its position in shares of Sangamo Therapeutics by 28.2% during the fourth quarter. Meritage Portfolio Management now owns 227,000 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 50,000 shares in the last quarter. Hedges Asset Management LLC bought a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $52,000. Oracle Investment Management Inc. acquired a new stake in shares of Sangamo Therapeutics in the third quarter valued at approximately $677,000. Finally, Prelude Capital Management LLC bought a new position in Sangamo Therapeutics in the 3rd quarter worth approximately $67,000. 56.92% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.